Compare Revvity Inc (RVTY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Thomson Reuters Corp — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Thomson Reuters Corp trades at $103.21 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 2.6× Revvity Inc's market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Thomson Reuters Corp for 63 Days on average.
| RVTY | TRI | |
|---|---|---|
Market Cap | $16.98B | $43.89B |
Volume | 1,456,900 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $157.36 | $163.45 |
52-Week Low | $82.26 | $76.55 |
Typical Hold Time | 12 Days | 63 Days |
Enterprise Value | $19.30B | $46.51B |
Dividend Yield | 0.18% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Thomson Reuters (TRI) trades at $101.55, up 2.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 75.7% gross margins and 21.22% net income margins, though Q4 2025 earnings slightly missed expectations. Recent strategic moves include divesting its printing unit to focus on technology offerings and launching a proprietary AI model, positioning for future growth in legal tech and content services.
Outlook remains positive with analyst consensus price target of $133.25 (31% upside) and 52% buy ratings. Key risks include cybersecurity incidents and execution of AI strategy. Revenue growth is projected at 4% for 2026, supported by recurring revenue streams and organic growth in core businesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
